LAKE FOREST, Calif., April 20, 2006 (PRIMEZONE) -- Apria Healthcare Group Inc. (NYSE:AHG), the nation's leading home healthcare company, responded today to a recent press release by Rotech Healthcare Inc. concerning Medicare reimbursement of Budesonide, a respiratory drug. Apria is not materially impacted by this development. Compared to 2005, the overall impact of this change is forecasted to be a reduction of $3 million in revenue. Apria reaffirms its previous EPS guidance for 2006 of $1.74 to $1.78, including the adoption of SFAS 123R, expensing of stock options.
Apria provides home respiratory therapy, home infusion therapy and home medical equipment through approximately 500 branches serving patients in 50 states. With almost $1.5 billion in annual revenues, it is the nation's leading homecare company.
This release may contain statements regarding anticipated future developments that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Results may differ materially as a result of the risk factors included in the Company's filings with the Securities and Exchange Commission and other factors over which the Company has no control.